FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C. 20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average but	rden						
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Rozek Elizabeth				2. Issuer Name and Ticker or Trading Symbol Sagimet Biosciences Inc. [SGMT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owne						
(Last)	,	First) ENCES INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/18/2023							X	Consider (Green and Cook Septiments) Officer (Green (Specify below)) General Counsel and CCO			
155 BOVET ROAD, SUITE 303				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	1 '					
(Street)	ATEO C	CA	94402									X		•	Reporting Pers	
(City)	(5	State)	(Zip)	F	Rule 10b5-1(c) Transaction Indication											
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							to satisfy								
		T	able I - Non-D	erivati	ve S	Securiti	es Acq	uired, [Disp	osed of	, or Ben	eficially	Owned			
Date			action Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficial Owned Fo Reported	Form (D) o	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
					Code	v	Amount	(A) or (D)	Price	Transactio (Instr. 3 ar			(mau. 4)			
			Table II - De (e.ç							sed of, o			wned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)	action Derivative Ex		6. Date Exercisable and Expiration Date (Month/Day/Year) Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported	Owners Form:	Beneficial Ownership ct (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		Transactio (Instr. 4)	n(s)	
Stock Option (Right to Buy)	\$13.51	07/18/2023		D			242,142	(2)		04/19/2033	Common Stock	242,142	\$0	0	D	
Stock Option (Right to Buy)	\$13.51	07/18/2023		A		242,142		(2)		04/19/2033	Series A Common Stock	242,142	\$0	242,142	2 D	

Explanation of Responses:

- 1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
- 2. 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

/s/ Dennis Hom, Attorney-in-

07/20/2023

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.